News
Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch
Alphamab?s $100 million Series A last November for the oncology unit marked its first venture round in almost 10 years of existence. As it turned out, it was also a signal that founder and CEO Ting Xu was ready to bring in the cash flow he needs to com… […]
